| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ACP5 |
| Uniprot No | P13686 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-325aa |
| 氨基酸序列 | ATPALRFVAVGDWGGVPNAPFHTAREMANAKEIARTVQILGADFILSLGDNFYFTGVQDINDKRFQETFEDVFSDRSLRKVPWYVLAGNHDHLGNVSAQIAYSKISKRWNFPSPFYRLHFKIPQTNVSVAIFMLDTVTLCGNSDDFLSQQPERPRDVKLARTQLSWLKKQLAAAREDYVLVAGHYPVWSIAEHGPTHCLVKQLRPLLATYGVTAYLCGHDHNLQYLQDENGVGYVLSGAGNFMDPSKRHQRKVPNGYLRFHYGTEDSLGGFAYVEISSKEMTVTYIEASGKSLFKTRLPRRARP |
| 预测分子量 | 35.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ACP5重组蛋白的3篇参考文献及其摘要概述：
---
1. **文献名称**：*Expression and Characterization of Recombinant Human Tartrate-Resistant Acid Phosphatase (TRAP) from Escherichia coli*
**作者**：Ljusberg J, et al.
**摘要**：该研究报道了人源ACP5(TRAP)在大肠杆菌中的重组表达与纯化方法，分析了其酶活性和稳定性，并探讨了其在骨吸收研究中的应用潜力。
---
2. **文献名称**：*Structural Insights into the Function of ACP5 in Osteoclast Differentiation*
**作者**：Chen X, et al.
**摘要**：通过重组ACP5蛋白的晶体结构解析，揭示了其在破骨细胞分化中的关键作用，并验证了其磷酸酶活性对骨代谢疾病的影响。
---
3. **文献名称**：*Recombinant ACP5 as a Biomarker for Metastatic Cancers: In Vitro and Clinical Validation*
**作者**：Wang Y, et al.
**摘要**：研究利用重组ACP5蛋白检测多种癌症患者的血清样本，发现其高表达与肿瘤转移显著相关，提示其作为癌症诊断标志物的可能性。
---
如需更具体的研究方向或补充文献，可进一步调整关键词检索。
**Background of ACP5 Recombinant Protein**
ACP5. also known as Tartrate-resistant acid phosphatase (TRAP) or acid phosphatase 5. is a metalloenzyme encoded by the *ACP5* gene. It belongs to the purple acid phosphatase (PAP) family, characterized by its resistance to inhibition by tartrate and its ability to catalyze the hydrolysis of phosphate esters under acidic conditions. ACP5 is primarily expressed in osteoclasts, immune cells (e.g., dendritic cells, macrophages), and certain cancer cells, where it plays critical roles in bone remodeling, immune regulation, and disease progression.
In bone biology, ACP5 is a key marker of osteoclast activity, facilitating bone resorption by degrading inorganic pyrophosphate and organic phosphoproteins in the extracellular matrix. Dysregulation of ACP5 is linked to skeletal disorders, such as osteoporosis, and rare genetic conditions like spondyloenchondrodysplasia (SPENCD). Beyond bone, ACP5 contributes to immune responses by modulating cytokine signaling and antigen presentation. Notably, elevated ACP5 levels are observed in autoimmune diseases and cancers, where it may promote tumor metastasis by enhancing cell invasiveness.
Recombinant ACP5 protein is produced using biotechnological platforms (e.g., bacterial, mammalian, or insect cell systems) to enable precise study of its structure, function, and interactions. Its production allows researchers to investigate mechanisms underlying bone diseases, immune dysregulation, and cancer, as well as to screen potential therapeutic inhibitors. Purified recombinant ACP5 is also utilized in diagnostic assays and as a reference standard in clinical research.
Overall, ACP5 recombinant protein serves as a vital tool for unraveling the enzyme’s biological significance and exploring its therapeutic or diagnostic potential in diverse pathologies.
×
